DIABETES MELLITUS WITH NEORAL (CYCLOSPORINE) VS. PROGRAF (TACROLIMUS) BASED REGIMENS AFTER KIDNEY TRANSPLANT DIABETES MELLITUS WITH NEORAL (CYCLOSPORINE) VS. PROGRAF (TACROLIMUS) BASED REGIMENS AFTER KIDNEY TRANSPLANT A randomized, three arm, parallel group, open label, prospective study of 3 immunosuppressive regimens [Prograf+azatioprine(AZA) vs Neoral+mycophenolate mofetil(MMF) vs Prograf +MMF] was performed in adult recipients of first cadaver kidney transplants at 15 sites. Prograf was initially dosed at 0.15-0.20 mg/kg/day orally to achieve target trough levels of 8-16ng/ml for the first 3 months and 5-15ng/mL thereafer. Neoral was initially dosed at 8-10 mg/kg/day orally to achieve-target trough levels of 200-4Oong/ml for the first 3 months and 100-3OOng/mL thereafter. All patients received the same maintenance corticosteroid regimens. Antilymphocyte induction was used only in patients with delayed graft function. 224 patients were randomized and transplanted. 156 patients have completed 6 months post-transplant follow-up of whom 105 patients did not have diabetes mellitus pre-transplant The incidence of post-transplant diabetes mellitus (PTDM), defined as new insulin use for 30days was: Prograf +AZA 10.5%(n=4). Neoral+MMF 6.5%(n=2) Prograf+MMF 0%(n=0). The percentage of patients on insulin at 6 months post-transplant was: Prograf+AZA 7.9% (n=3), Neoral+MMF 6.5%(n=2), Prograf+MMF 2.8%(n=1).
